ACHE and Alzheimer disease: The first studies on the use of chitosan nanosystems for AD management involved the incorporation of the acetylcholinesterase inhibitors tacrine [50] and rivastigmine [51] into chitosan NPs with particle sizes of 41 ± 7 nm and 47 ± 4 nm, respectively.